Concinnity Genetics

Concinnity Genetics is a private, pre-clinical biotech leveraging synthetic biology and a proprietary AI platform to develop modular RNA control systems for gene therapies. Founded as a spin-out from the University of Edinburgh, the company addresses a critical safety gap in the field by creating therapies that can self-regulate in response to molecular signals. Its platform-agnostic approach is designed to partner with gene therapy developers to enhance the safety profile of their pipelines. Concinnity is pre-revenue and operates as a platform technology company seeking partnerships to advance its technology into therapeutic applications.

Proprietary AI platform combined with synthetic biology to design modular, synthetic RNA-based control systems for gene therapies. The systems are inserted into the 3' UTR of gene cassettes and can be engineered to respond to specific molecular signals to dynamically regulate therapeutic gene expression.

Concinnity competes with other companies developing gene therapy safety switches, such as those using small-molecule-dependent protein degrons or engineered cell surface receptors. Its differentiation lies in its fully synthetic, RNA-based, AI-designed approach, which claims greater modularity and input flexibility than systems derived from natural biology.